Somu Subramaniam

Somu Subramaniam is the co-founder and Managing Partner of New Science Ventures. Somu serves on the Board of Directors of Achronix Semiconductor Corporation, BrightVolt, Cambridge Epigenetix, Dali Wireless, Ferric, Inc, Oxyrane, Pakal Technologies, Paragraf, ProterixBio, Ralexar Therapeutics, Resolve Therapeutics, Svelte Medical Systems, Ventyx Biosciences, Inc and Zeotap GmbH. Somu has also served on the Boards of Dezima Pharma (acquired by Amgen), Ception Therapeutics (acquired by Cephalon), BioVex (acquired by Amgen), Lightwire (acquired by Cisco), K2M (acquired by Welsh Carson) and Akarna Therapeutics (acquired by Allergan).

Prior to founding NSV, Somu was a director at McKinsey & Company where he advised leading multinational companies in the pharmaceuticals, medical devices, biotechnology, photonics, software and semiconductor industries. At McKinsey, Somu was leader of the Strategy Practice, the Technology Practice, the Biotechnology Group, and the Healthcare Practice. He also served on the firm’s Investment Committee and led its Equity Portfolio Committee. Somu holds a B.Tech. degree from the Indian Institute of Technology and an M.B.A. from Harvard Business School.